Itraconazole immediate release formulation
The present invention relates to active pellets without a specific inert starting seed size and without a seal coat, which may be compressed into a tablet or loaded into a capsule to form an orally administrable dosage formulation for an antifungal agent.
1 . An active pellet consisting essentially of:
A) an inert starting seed;
B) an antifungal agent;
C) a binder; and
d) optionally an alkaline agent.
2 . The active pellet according to claim 1 , wherein the inert starting seed has a mesh size of 15-40.
3 . The active pellets according to claim 1 , wherein the inert starting seed has a mesh size of 18-20.
4 . The active pellets according to claim 1 , wherein the inert starting seeds are selected from the group consisting of plastic resins, silica, glass, microcrystalline cellulose, hydroxyapatite, sodium chloride, potassium chloride, calcium carbonate, magnesium carbonate, activated carbon, citric acid, fumaric acid, tartaric acid, ascorbic acid, oligosaccharides, glucose, rhamnose, galactose, lactose, sucrose, mannitol, sorbitol, dextrin, maltodextrin, cellulose, sodium carboxymethyl cellulose and starch.
5 . The active pellets according to claim 2 , wherein the inert starting seed is a sugar sphere.
6 . The active pellets according to claim 2 , wherein the inert starting seed is microcrystalline cellulose.
7 . The active pellets according to claim 2 , wherein the antifungal is itraconazole.
8 . The active pellets according to claim 2 , wherein the binder is selected from the group consisting of polyvinyl pyrrolidone, hydroxyethyl cellulose, hydroxypropyl cellulose, Hydroxypropyl methylcellulose, polyacrylate, ethylcellulose, or mixtures thereof.
9 . The active pellets, according to claim 7 , wherein the binder is hydroxypropyl methylcellulose.
10 . A pharmaceutical composition comprising a capsule and a plurality of active pellets as defined in claim 1 .
11 . An active pellet consisting essentially of:
A) at least 35% by weight of a inert starting seed;
B) 10-50% by weight of an antifungal agent;
C) 10-50% by weight of a binder; and
D) 0-5% by weight of an alkaline agent.
12 . An active pellet, according to claim 11 , consisting essentially of:
A) 35-55% by weight of an inert starting seed;
B) 15-40% by weight of an antifungal agent;
C) 25-40% by weight of a binder; and
D) 0-3% by weight of an alkaline agent.
13 . The active pellet according to claim 11 , wherein the inert starting seed has a mesh size of 15-40.
14 . The active pellets according to claim 11 , wherein the inert starting seed has a mesh size of 18-20.
15 . The active pellets according to claim 11 , wherein the inert starting seeds are selected from the group consisting of plastic resins, silica, glass, microcrystalline cellulose, hydroxyapatite, sodium chloride, potassium chloride, calcium carbonate, magnesium carbonate, activated carbon, citric acid, fumaric acid, tartaric acid, ascorbic acid, oligosaccharides, glucose, rhamnose, galactose, lactose, sucrose, mannitol, sorbitol, dextrin, maltodextrin, cellulose, sodium carboxymethyl cellulose and starch.
16 . The active pellets according to claim 13 , wherein the inert starting seed is a sugar sphere.
17 . The active pellets according to claim 13 , wherein the inert starting seed is microcrystalline cellulose.
18 . The active pellets according to claim 13 , wherein the antifungal is itraconazole.
19 . The active pellets according to claim 13 , wherein the binder is selected from the group consisting of polyvinyl pyrrolidone, hydroxyethyl cellulose, hydroxypropyl cellulose, Hydroxypropyl methylcellulose, polyacrylate, ethylcellulose, or mixtures thereof.
20 . The active pellets, according to claim 19 , wherein the binder is hydroxypropyl methylcellulose.
21 . A pharmaceutical composition comprising a capsule and a plurality of active pellets as defined in claim 11 .
22 . The pharmaceutical capsule as defined in claim 10 that exhibits a peak plasma level between 3 and 9 hours after administration.
23 . The pharmaceutical capsule as defined in claim 10 that exhibits a C max of less than 100 ng/ml.
24 . The pharmaceutical capsule as defined in claim 10 that exhibits a C max of less than 90 ng/ml.
25 . The pharmaceutical capsule as defined in claim 10 that exhibits a C max of between 40 ng/ml and 80 ng/ml.
27 . The pharmaceutical capsule as defined in claim 11 that exhibits a peak plasma level between 3 and 9 hours after administration.
28 . The pharmaceutical capsule as defined in claim 11 that exhibits a C max of less than 100 ng/ml.
29 . The pharmaceutical capsule as defined in claim 11 that exhibits a C max of less than 90 ng/ml.
30 . The pharmaceutical capsule as defined in claim 11 that exhibits a C max of between 40 ng/ml and 80 ng/ml.
31 . An antifungal pharmaceutical dosage form for oral administration consisting essentially of:
a) a geletin capsule; and
b) a plurality of active pellets, wherein each pellet consists essentially of:
i) at least 40% by weight of an 18-20 mesh sugar sphere.
ii) 10-50% by weight of itraconazole;
iii) 10-50% by weight of a binder; and
iv) 0-5% by weight of an alkaline agent.
32 . A pharmaceutical tablet comprising a plurality of active pellets as defined in claim 1 and convention tabletting excipients.
33 . A pharmaceutical tablet comprising a plurality of active pellets as defined in claim 11 and conventional tabletting excipients.